Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Marc Ferrante, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean Frederic Colombel, Silvio Danese, Marla Dubinsky, Brian G. Feagan, Tadakazu Hisamatsu, Allen Lim, James O. Lindsay, Edward V. Loftus, Julián Panés, Laurent Peyrin-Biroulet, Zhihua Ran, David T. Rubin, William J. Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra SongKristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W. Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Geert D'Haens

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial'. Together they form a unique fingerprint.

Medicine & Life Sciences